Stock Scorecard
Stock Summary for Atara Biotherapeutics Inc (ATRA) - $14.06 as of 10/29/2025 6:05:41 PM EST
Total Score
14 out of 30
Safety Score
35 out of 100
Currently on the following lists
None
Tim's Recommendation
Possible Buy
Growth List Algorithm Criteria for ATRA
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for ATRA
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for ATRA
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for ATRA
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for ATRA (35 out of 100)
| Stock Price Rating (Max of 10) | 5 |
| Historical Stock Price Rating (Max of 10) | 10 |
| Stock Price Trend (Max of 10) | 1 |
| Book Value (Max of 10) | 1 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 4 |
| Analyst Strong Buy Ratings (Max of 5) | 0 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 5 |
| Trading Volume (Max of 10) | 2 |
| Price to Earnings (Max of 10) | 7 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for ATRA
Financial Details for ATRA
Company Overview |
|
|---|---|
| Ticker | ATRA |
| Company Name | Atara Biotherapeutics Inc |
| Country | USA |
| Description | Atara Biotherapeutics, Inc. is a clinical-stage biotechnology company headquartered in South San Francisco, California, focused on allogeneic T-cell immunotherapy to treat cancer, autoimmune disorders, and viral infections. The company is advancing a compelling therapeutic platform that harnesses T-cells to meet significant unmet medical needs in complex diseases. With a robust pipeline of investigational therapies, Atara is well-positioned at the forefront of the immunotherapy landscape, aiming to improve patient outcomes and drive innovation in this critical sector of healthcare. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 6/30/2025 |
| Next Earnings Date | N/A |
Stock Price History |
|
| Last Day Price | 14.06 |
| Price 4 Years Ago | 394.00 |
| Last Day Price Updated | 10/29/2025 6:05:41 PM EST |
| Last Day Volume | 37,236 |
| Average Daily Volume | 58,604 |
| 52-Week High | 18.70 |
| 52-Week Low | 5.00 |
| Last Price to 52 Week Low | 181.20% |
Valuation Measures |
|
| Trailing PE | 21.12 |
| Industry PE | 23.04 |
| Sector PE | 40.93 |
| 5-Year Average PE | -28.65 |
| Free Cash Flow Ratio | 5.83 |
| Industry Free Cash Flow Ratio | 14.83 |
| Sector Free Cash Flow Ratio | 29.03 |
| Current Ratio Most Recent Quarter | 1.70 |
| Total Cash Per Share | 2.41 |
| Book Value Per Share Most Recent Quarter | -5.02 |
| Price to Book Ratio | 1.97 |
| Industry Price to Book Ratio | 29.98 |
| Sector Price to Book Ratio | 32.16 |
| Price to Sales Ratio Twelve Trailing Months | 0.57 |
| Industry Price to Sales Ratio Twelve Trailing Months | 33.56 |
| Sector Price to Sales Ratio Twelve Trailing Months | 16.96 |
| Analyst Buy Ratings | 4 |
| Analyst Strong Buy Ratings | 0 |
Share Statistics |
|
| Total Shares Outstanding | 7,023,000 |
| Market Capitalization | 98,743,380 |
| Institutional Ownership | 45.76% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | 69.07% |
| Reported EPS 12 Trailing Months | 0.72 |
| Reported EPS Past Year | 3.69 |
| Reported EPS Prior Year | -7.45 |
| Net Income Twelve Trailing Months | 5,795,000 |
| Net Income Past Year | -85,403,000 |
| Net Income Prior Year | -276,126,000 |
| Quarterly Revenue Growth YOY | -38.60% |
| 5-Year Revenue Growth | 0.00% |
| Operating Margin Twelve Trailing Months | 26.90% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 16,903,000 |
| Total Cash Past Year | 25,030,000 |
| Total Cash Prior Year | 25,841,000 |
| Net Cash Position Most Recent Quarter | 16,903,000 |
| Net Cash Position Past Year | 25,030,000 |
| Long Term Debt Past Year | 0 |
| Long Term Debt Prior Year | 0 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 0.00 |
| Equity to Debt Ratio Most Recent Quarter | 0.00 |
| Total Stockholder Equity Past Year | -97,283,000 |
| Total Stockholder Equity Prior Year | -99,231,000 |
| Total Stockholder Equity Most Recent Quarter | -35,041,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -64,006,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -9.11 |
| Free Cash Flow Past Year | -68,963,000 |
| Free Cash Flow Prior Year | -194,200,000 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | False |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.49 |
| MACD Signal | 0.60 |
| 20-Day Bollinger Lower Band | 7.58 |
| 20-Day Bollinger Middle Band | 11.86 |
| 20-Day Bollinger Upper Band | 16.15 |
| Beta | 0.26 |
| RSI | 57.05 |
| 50-Day SMA | 27.85 |
| 150-Day SMA | 0.00 |
| 200-Day SMA | 66.24 |
System |
|
| Modified | 10/29/2025 6:05:43 PM EST |